AstraZeneca Plc (AZN:US), the U.K.'s second- biggest drugmaker, lost its appeal of a U.S. court ruling that opens the door to generic competition for the company's Toprol- XL blood-pressure treatment.
The U.S. Court of Appeals for the Federal Circuit in Washington today turned down AstraZeneca's bid for a rehearing of a decision that a patent on the drug is invalid because the chemical compound is covered by another patent. The July ruling was a victory for Novartis AG (NOVN)'s Eon Labs, KV Pharmaceutical Co. (KVPHQ:US) and Watson Pharmaceuticals Inc. (WPI:US)'s Andrx unit.
U.S. sales of Toprol-XL contributed $670 million, or 27 cents a share, in the first six months of 2007 to London- based AstraZeneca's revenue. The company's sales of the drug are expected to plunge due to generic competition.
The appeals court ruled 2-to-1 in July that one of the patents for the drug covers the same thing as a different patent that expired. The decision not to rehear the case was announced on the court's Web site.
Officials with St. Louis-based KV, London-based AstraZeneca and Basel, Switzerland-based Novartis didn't immediately return messages seeking comment.
AstraZeneca's American depositary receipts (AZN:US), each representing one ordinary share, rose $1.18 to $52.30 in New York Stock Exchange composite trading. KV shares rose 4 cents to $29.14.
The case is In Re Metoprolol Succinate Patent Litigation, 06-1254, U.S. Court of Appeals for the Federal Circuit (Washington).
To review the invalidated patent through the U.S. Patent and Trademark Office's Web site, search for patent number 5,081,154 at http://patft.uspto.gov/netahtml/PTO/srchnum.htm.
The other patent is 5,001,161.
To contact the reporters on this story: Jeff St.Onge in Washington at email@example.com; Susan Decker in Washington at firstname.lastname@example.org.
To contact the editors responsible for this story: Patrick Oster at email@example.com; Robert Simison at firstname.lastname@example.org.